Report in the journal Molecular Cell crucial and surprising first steps that promote resistance to ciprofloxacin, or cipro for short, one of the most commonly prescribed antibiotics. The findings point at potential strategies that could prevent bacteria from developing resistance, extending the effectiveness of new and old antibiotics.
The community of microbes living in and on our bodies may be acting as a reservoir for antibiotic resistance, according to new research from the Earlham Institute and Quadram Institute in Norwich.
Researchers at Argonne’s Advanced Photon Source have used serial crystallography, a way to make molecular movies, to see in real time the mechanisms involved in an enzyme that confers antibiotic resistance to a certain bacterium.
A new study identified a compound that prevents C. diff infection. Researchers are now using this compound to develop new drug candidates that might eventually offer a way to prevent serious C. diff infections.
Scientists from the French National Reference Center for Escherichia coli, Shigella and Salmonella at the Institut Pasteur who have been monitoring Shigella in France for several years have detected the emergence of extensively drug-resistant (XDR) strains of Shigella sonnei.
Staphylococcus aureus. You may have had it in connection with a wound infection. In most cases, it will pass without treatment, while severe cases may require antibiotics, which kills the bacteria. This is the case for the majority of the population. In fact, many of us – though we feel perfectly fine – carry staphylococci in the nose, a good, moist environment in which the bacteria thrive.
A new study by Tufts University researchers found a molecule that could be a target for treatment in patients who have become resistant to traditional anti-seizure drugs
The human intestine is an environment inhabited by many bacteria and other microorganisms collectively known as the gut microbiome, gut microbiota or intestinal flora.
Hackensack Meridian Mountainside Medical Center has been recognized as a Silver Level Antimicrobial Stewardship Recognition Program award recipient by the NJDOH.
The constant evolution of new COVID-19 variants makes it critical for clinicians to have multiple therapies in their arsenal for treating drug-resistant infections. Researchers have now discovered that a new class of oral drugs that acts directly on human cells can inhibit a diverse range of pathogenic SARS-CoV-2 strains. In their newly published study, the team found a novel mechanism through which the gene that expresses angiotensin converting enzyme-2 (ACE-2)—the cellular receptor to which SARS-CoV-2 binds so that it can enter and infect the cell—is turned on.
Cedars-Sinai and its affiliate Huntington Health are collaborating on a new Epilepsy Monitoring Unit to bring treatment and care closer to epilepsy patients in the San Gabriel Valley
New methodology and tools his team developed by phage expert Graham Hatful provides the opportunity to watch in unprecedented detail as a phage attacks a bacterium.
Scientists at St. Jude Children’s Research Hospital showed an effective method to avoid activating a major cellular detoxification receptor to overcome drug resistance and toxicity.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include a new understanding of how HPV drives cancer development, a combination therapy to overcome treatment resistance in mantle cell lymphoma, novel insights into memory T cell formation and potential therapeutic strategies for brain cancers, improved survival outcomes for metastatic colorectal cancer, targeting myeloperoxidase to improve immunotherapy responses in melanoma, and preclinical results of a combination therapy that could effectively treat a subset of acute myeloid leukemia.
A new study shows that a 2018 California bill banning routine antibiotic use in livestock is linked with reduction in some antibiotic-resistant infections
SHRO Founder Antonio Giordano contributes to a new publication on the use of liquid biopsy to assess the treatment response and find mutations that confer resistance to cancer therapies.
Scientists at the Paul Scherrer Institute PSI have used the Swiss X-ray free-electron laser SwissFEL and the Swiss Light Source SLS to make a film that could give a decisive boost to developing a new type of drug.
In a potential game changer for the treatment of superbugs, a new class of antibiotics was developed that cured mice infected with bacteria deemed nearly “untreatable” in humans — and resistance to the drug was virtually undetectable.
Antimicrobial resistance represents one of the top 10 global public health threats according to the World Health Organization, and scientists have been scrambling to find new tools to cure the most deadly drug-resistant infections.
MD Anderson and Federation Bio announced a strategic collaboration to design and manufacture a synthetic microbial consortium with the goal of improving responses in immunotherapy-resistant cancers.
Kevin Garey, professor of pharmacy practice and translational research at the University of Houston College of Pharmacy is reporting the first well-controlled study to demonstrate that a microbiome therapeutic, SER-109, is associated with significant quality of life improvement in patients with the debilitating recurrent infection and disease caused by Clostridium difficile (or C. diff).
In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted in substantially better responses than standard treatments. Mirvetuximab soravtansine was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in November 2022.
Johns Hopkins Medicine investigators say their research indicates a new combination of drugs is needed to find an effective treatment for TB meningitis due to multidrug-resistant (MDR) strains
UC San Diego and its collaborating partners have been awarded $10 million from the Howard Hughes Medical Institute to leverage the biomedical promise of viruses known as bacteriophages as new therapeutic agents in the fight against the rising crisis of antibiotic-resistant bacterial infections.
Researchers at University of California San Diego and UC Riverside have further elucidated the molecular pathway used by the SARS-CoV-2 virus to infect human lung cells, identifying a key host-cell player that may prove a new and enduring therapeutic target for treating COVID-19.
A new paper in Evolution, Medicine, and Public Health, published by Oxford University Press, indicates that antibiotic resistance may result from poor hygiene practices in hospitals or other medical facilities.
Human cells are often a mixture of both abnormal and normal DNA – a mosaic, so to speak, and like the art form, this complex montage is difficult to understand. Neuroscience researchers are training computers to unveil new methods for DNA mosaic recognition.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
A RUDN University biologist and colleagues from Iran have found bacteria that can become a potential biological drug against a pest fungus that infects rice. Unlike chemical fungicides, such a bio-agent is harmless to the environment and does not lead to the formation of biological resistance.
Antibiotic residues in wastewater and wastewater treatment plants in the regions around China and India risk contributing to antibiotic resistance, and the drinking water may pose a threat to human health, according to a comprehensive analysis from Karolinska Institutet published in The Lancet Planetary Health.
High levels of ammonia in tumors leads to fewer T cells and immunotherapy resistance in mouse models of colorectal cancer, new findings from the University of Michigan Rogel Cancer Center revealed. Researchers found that ammonia inhibits the growth and function of T cells, which are vital for anti-tumor immunity. The findings appear in Cell Metabolism.
Researchers have designed and synthesized analogs of a new antibiotic that is effective against multidrug-resistant bacteria, opening a new front in the fight against these infections.